Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
Susan A. Murphy is the Mallinckrodt Professor of Statistics and of Computer Science at Harvard University, with affiliations to the Kempner Institute. She leads the Statistical Reinforcement Learning Lab, focusing on developing algorithms to inform sequential decision-making in health, particularly for Just-in-Time Adaptive Interventions (JITAIs) and micro-randomized trials (MRTs). Her work is funded by NIH institutes, including NIDA, NHLBI, and NIBIB. Dr. Murphy has been awarded a MacArthur Fellowship (2013) and is a member of the National Academy of Medicine (2014) and the National Academy of Sciences (2016). Her research integrates statistical methods with computer science techniques to optimize mobile health interventions. She collaborates with d3Lab and mDOT on projects like HeartSteps and Sense2Stop, evaluating real-time treatment policies. Notable contributions include advancing MRT designs, sample size calculations, and reinforcement learning algorithms for personalized healthcare. Dr. Murphy advises a large team of postdocs, graduate students, and undergraduates, many of whom hold academic and industry roles globally. She emphasizes engagement in digital interventions, balancing personalization with ethical considerations. Her lab’s work spans algorithm development, clinical trial design, and causal inference, aiming to improve health outcomes through adaptive interventions.
Yao Yang is an Assistant Professor in the Department of Chemistry and Chemical Biology at Cornell University's College of Arts and Sciences. His research focuses on developing multimodal operando electron microscopy and synchrotron X-ray methods to probe electrochemical dynamics at solid-liquid interfaces for energy materials. PhD, Cornell University (2021) Miller Postdoctoral Fellow, UC Berkeley (2021-2024) Research interests span fundamental electrochemistry and energy material interfaces, particularly CO2 reduction, clean H2 production, and rechargeable batteries. The Yang group specializes in operando electrochemical liquid-cell scanning transmission electron microscopy (EC-STEM) and correlative synchrotron X-ray methods at Cornell Center for Materials Research (CCMR) and Cornell High Energy Synchrotron Source (CHESS). Recent publications highlight atomic-scale imaging of catalyst dynamics, Tafel slope analysis, and epitaxial growth techniques for enhanced electrocatalysts. Articles demonstrate interdisciplinary approaches combining electrochemistry, nanoscience, and advanced characterization. Scientific Awards: 2025 ACS Materials and Interfaces Outstanding Presentations by Young Investigators Award 2024 Journal of Materials Research Distinguished Invited Speaker Miller Postdoctoral Fellowship (2021-2024) 2023 Best Early Career Presentation at MRS Spring 2022 ACS AC/DC Rising Stars in Analytical Chemistry Contact: yaoyang@cornell.edu
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Dr. Yogambha Ramaswamy is a Senior Lecturer in the School of Biomedical Engineering at The University of Sydney and a member of the Sydney Nano Institute. She holds a Master’s in Biotechnology from the University of Queensland and a PhD in Biomedical Engineering from the University of Sydney (2009). Her postdoctoral career began as a Vice-Chancellor’s Postdoctoral Research Fellow at the University of New South Wales, followed by a Peter Doherty Early Career Fellowship in 2013 before joining the University of Sydney in 2015. Dr. Ramaswamy’s research focuses on biomaterials, tissue engineering, and mechanobiology, with a particular emphasis on developing calcium silicate-based ceramics and biopolymers for orthopedic and regenerative applications. Her recent work explores the role of physical cues in modulating stem and cancer cell behavior. She teaches courses such as AMME1961 (Introduction to Biomedical Engineering B) and AMME5962 (Introduction to Mechanobiology). Her research has been supported by grants including the NHMRC Early Career Fellowship and collaborations with institutions like the CSIR-Indian Institute of Chemical Technology and the University of Otago. Her publications span biomaterials, nanotechnology, and mechanobiology, with recent work addressing atherosclerosis, hydrogel design, and nanomedicine. She currently supervises PhD students Frank (biomaterials) and Alexander (atherosclerosis research).
Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Sushmita Roy is a Professor at the University of Wisconsin–Madison, affiliated with the Department of Computer Sciences and the College of Letters and Science. Her research focuses on developing computational methods in statistical machine learning to understand gene regulatory networks in living cells, particularly under environmental, developmental, disease, and evolutionary contexts. She explores bulk and single-cell genomic data integration to study processes like cell fate specification, host-microbe interactions, and diseases such as cancer and neurodevelopmental disorders. Her work emphasizes three key areas: inference of genome-scale transcriptional networks, evolutionary analysis of regulatory networks, and 3D genome organization dynamics. Roy’s lab collaborates across disciplines, leveraging genomic data from plant and mammalian systems. She has contributed to methodologies for analyzing chromatin accessibility, single-cell profiling, and network-based models of pathogen systems. Her affiliations include Wisconsin Institutes for Discovery, and she is a leader in computational biology and systems genomics research.
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
Prof. Dr. Helmuth Gehart is a faculty member at the Institute of Molecular Health Sciences , ETH Zurich . He leads the Tumor and Stem Cell Dynamics research group, focusing on dynamic cell identity in regeneration and cancer. Research Interests : Stem cell-environment interactions, organoid technology, single-cell sequencing, and mechanisms of tissue repair/tumorigenesis. Publications : 10+ articles (2015-2024) on organoid models, stem cell dynamics, and cancer biology.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Changhuei Yang is the Thomas G. Myers Professor of Electrical Engineering, Bioengineering, and Medical Engineering at California Institute of Technology, serving as Executive Officer for Electrical Engineering and Investigator at Heritage Medical Research Institute. He holds a Ph.D. and three master's degrees from MIT, with appointments at Caltech since 2003. Research focuses on: Advanced microscopy techniques including Fourier Ptychography Wavefront shaping for biological tissue imaging Optical phase conjugation for deep-tissue applications Compact medical devices for cerebral monitoring Publications demonstrate leadership in computational imaging, with recent advances in stain-free embryo analysis, portable cerebral blood flow monitors, and high-resolution volumetric imaging techniques using neural representations. Honored as National Academy of Inventors member. Research applications span deep-tissue biochemical imaging, incisionless surgery, and optogenetic activation systems.
Professor Carlo Pappone is a Full Professor of Cardiology at Vita-Salute San Raffaele University (since 2019) and Director of the Arrhythmology Department at IRCCS Policlinico San Donato Hospital (since 2015). He has held previous academic/clinical leadership roles at IRCCS San Raffaele Hospital (2000-2010), Villa Maria Cecilia Hospital (2010-2015), and University of Naples Federico II (1990-2000). With 212 publications in top journals like NEJM, JAMA, and Circulation, he has made significant contributions to cardiac arrhythmia research. Current Positions Vita-Salute San Raffaele University (2019-present): Full Professor of Cardiology IRCCS Policlinico San Donato Hospital (2015-present): Director of Arrhythmology Department Previous Roles University of Naples Federico II (1990-2000) University of Michigan Ann Harbor (1990-2000) IRCCS San Raffaele Hospital (2000-2010) Villa Maria Cecilia Hospital (2010-2015) Research Focus: Specializing in cardiovascular diseases, his work spans atrial fibrillation ablation techniques, Brugada syndrome pathogenesis, heart failure device therapy, and ion channel disorders. His H-index of 53 and 18,407 citations reflect his substantial academic impact. Notable Scientific Contributions Author of 44 patents Principal Investigator in 14 clinical trials (clinicaltrials.gov) Developed circumferential pulmonary vein ablation technique Innovator in biventricular pacing systems for heart failure Pioneered research on non-excitatory current for cardiac contractility Scientific Recognition Awarded as Elite Reviewer of JACC (2005) Editorial Board Member of 6 leading journals Reviewer for NEJM, JAMA, Lancet, and Nature Medicine Education Medical Doctorate: University of Naples Federico II
